Association of Metabolic Comorbidities with Pediatric Psoriasis: A Systematic Review and Meta-Analysis
- Author:
Soo Ick CHO
1
;
Ye Eun KIM
;
Seong Jin JO
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Annals of Dermatology 2021;33(3):203-213
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:An evident relationship has been shown between psoriasis and metabolic comorbidities. However, the results in pediatric psoriasis vary from study to study, and no meta-analysis exists on the association of metabolic comorbidities with pediatric psoriasis. Objective: To evaluate the association between psoriasis and metabolic comorbidities in pediatric patients.
Methods:We searched articles published in PubMed, EMBASE, and Cochrane Library databases from inception to April 30, 2019. All observational studies reporting the prevalence of obesity or metabolic comorbidities in pediatric patients with psoriasis were included.
Results:The meta-analysis included 16 unique studies meeting the inclusion criteria. The pooled odds ratios in pediatric patients with psoriasis was 2.40 (95% confidence interval [CI], 1.60∼3.59) for obesity (13 studies), 2.73 (95% CI, 1.79∼ 4.17) for hypertension (8 studies), 2.01 (95% CI, 1.09∼3.73) for diabetes mellitus (8 studies), 1.67 (95% CI, 1.42∼1.97) for dyslipidemia (7 studies), and 7.49 (95% CI, 1.86∼30.07) for metabolic syndrome (4 studies).
Conclusion:Pediatric patients with psoriasis showed a significantly higher prevalence of obesity, hypertension, diabetes, dyslipidemia, and metabolic syndrome. Adequate monitoring and timely management of metabolic comorbidities should be considered in these patients.
